These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 33167838)

  • 1. Cerebrospinal Fluid and Blood CX3CL1 as a Potential Biomarker in Early Diagnosis and Prognosis of Dementia.
    Kulczyńska-Przybik A; Słowik A; Mroczko P; Borawski B; Groblewska M; Borawska R; Mroczko B
    Curr Alzheimer Res; 2020; 17(8):709-721. PubMed ID: 33167838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glial activation and inflammation along the Alzheimer's disease continuum.
    Nordengen K; Kirsebom BE; Henjum K; Selnes P; Gísladóttir B; Wettergreen M; Torsetnes SB; Grøntvedt GR; Waterloo KK; Aarsland D; Nilsson LNG; Fladby T
    J Neuroinflammation; 2019 Feb; 16(1):46. PubMed ID: 30791945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease.
    Baldacci F; Toschi N; Lista S; Zetterberg H; Blennow K; Kilimann I; Teipel S; Cavedo E; Dos Santos AM; Epelbaum S; Lamari F; Dubois B; Floris R; Garaci F; Bonuccelli U; Hampel H
    Alzheimers Dement; 2017 Sep; 13(9):993-1003. PubMed ID: 28263742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.
    Hellwig K; Kvartsberg H; Portelius E; Andreasson U; Oberstein TJ; Lewczuk P; Blennow K; Kornhuber J; Maler JM; Zetterberg H; Spitzer P
    Alzheimers Res Ther; 2015 Dec; 7():74. PubMed ID: 26698298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid levels of YKL-40 in prodromal Alzheimer's disease.
    Wang L; Gao T; Cai T; Li K; Zheng P; Liu J;
    Neurosci Lett; 2020 Jan; 715():134658. PubMed ID: 31794792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort.
    Kester MI; Teunissen CE; Sutphen C; Herries EM; Ladenson JH; Xiong C; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
    Alzheimers Res Ther; 2015 Sep; 7(1):59. PubMed ID: 26383836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.
    Sanfilippo C; Forlenza O; Zetterberg H; Blennow K
    J Neural Transm (Vienna); 2016 Dec; 123(12):1443-1447. PubMed ID: 27531278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.
    Craig-Schapiro R; Perrin RJ; Roe CM; Xiong C; Carter D; Cairns NJ; Mintun MA; Peskind ER; Li G; Galasko DR; Clark CM; Quinn JF; D'Angelo G; Malone JP; Townsend RR; Morris JC; Fagan AM; Holtzman DM
    Biol Psychiatry; 2010 Nov; 68(10):903-12. PubMed ID: 21035623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
    Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
    Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Relationships between Cerebrospinal Fluid Glial (CXCL12, CX3CL, YKL-40) and Synaptic Biomarkers (Ng, NPTXR) in Early Alzheimer's Disease.
    Kulczyńska-Przybik A; Dulewicz M; Doroszkiewicz J; Borawska R; Słowik A; Zetterberg H; Hanrieder J; Blennow K; Mroczko B
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease.
    Westin K; Buchhave P; Nielsen H; Minthon L; Janciauskiene S; Hansson O
    PLoS One; 2012; 7(1):e30525. PubMed ID: 22303443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease.
    Mroczko B; Groblewska M; Zboch M; Muszyński P; Zajkowska A; Borawska R; Szmitkowski M; Kornhuber J; Lewczuk P
    J Alzheimers Dis; 2015; 43(3):1031-7. PubMed ID: 25159667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease.
    Perrin RJ; Craig-Schapiro R; Malone JP; Shah AR; Gilmore P; Davis AE; Roe CM; Peskind ER; Li G; Galasko DR; Clark CM; Quinn JF; Kaye JA; Morris JC; Holtzman DM; Townsend RR; Fagan AM
    PLoS One; 2011 Jan; 6(1):e16032. PubMed ID: 21264269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF-AD study.
    Smith RG; Pishva E; Kouhsar M; Imm J; Dobricic V; Johannsen P; Wittig M; Franke A; Vandenberghe R; Schaeverbeke J; Freund-Levi Y; Frölich L; Scheltens P; Teunissen CE; Frisoni G; Blin O; Richardson JC; Bordet R; Engelborghs S; de Roeck E; Martinez-Lage P; Altuna M; Tainta M; Lleó A; Sala I; Popp J; Peyratout G; Winchester L; Nevado-Holgado A; Verhey F; Tsolaki M; Andreasson U; Blennow K; Zetterberg H; Streffer J; Vos SJB; Lovestone S; Visser PJ; Bertram L; Lunnon K
    Alzheimers Dement; 2024 Oct; 20(10):6722-6739. PubMed ID: 39193893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved Differential Diagnosis of Alzheimer's Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers.
    Khoonsari PE; Shevchenko G; Herman S; Remnestål J; Giedraitis V; Brundin R; Degerman Gunnarsson M; Kilander L; Zetterberg H; Nilsson P; Lannfelt L; Ingelsson M; Kultima K
    J Alzheimers Dis; 2019; 67(2):639-651. PubMed ID: 30614806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer's disease.
    Teuber-Hanselmann S; Rekowski J; Vogelgsang J; von Arnim C; Reetz K; Stang A; Jöckel KH; Wiltfang J; Esselmann H; Otto M; Tumani H; Herring A; Keyvani K
    J Neurol Neurosurg Psychiatry; 2020 Jan; 91(1):40-48. PubMed ID: 31371645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
    Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
    Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Relationship between Markers of Inflammation and Degeneration in the Central Nervous System and the Blood-Brain Barrier Impairment in Alzheimer's Disease.
    Muszyński P; Kulczyńska-Przybik A; Borawska R; Litman-Zawadzka A; Słowik A; Klimkowicz-Mrowiec A; Pera J; Dziedzic T; Mroczko B
    J Alzheimers Dis; 2017; 59(3):903-912. PubMed ID: 28697565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.